Inhaled Formoterol Diminishes Insulin-Induced Hypoglycemia in Type 1 Diabetes.

ABSTRACT:

Objective

Hypoglycemia is one of the major factors limiting implementation of tight glycemic control in patients with type 1 diabetes and is associated with increased morbidity and mortality during intensive insulin treatment. β-2 Adrenergic receptor (AR) agonists have been reported to diminish nocturnal hypoglycemia; however, whether long-acting inhaled β-2 AR agonists could potentially be used to treat or prevent hypoglycemia has not been established.

Research design and methods

Seven patients with type 1 diabetes and seven healthy control subjects received inhaled formoterol (48 μg), a highly specific β-2 AR agonist, or a placebo during a hyperinsulinemic-hypoglycemic clamp study to evaluate its capacity to antagonize the effect of insulin. In a second set of studies, fiv

SUBMITTER: Belfort-DeAguiar RD 

PROVIDER: S-EPMC4542274 | biostudies-literature | 2015 Sep

REPOSITORIES: biostudies-literature